Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland

ConclusionRIV  + ASA was a cost-effective treatment alternative compared with ASA in patients with CCS or symptomatic PAD in Finland.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research